Literature DB >> 20393308

Impact of gene patents and licensing practices on access to genetic testing for cystic fibrosis.

Subhashini Chandrasekharan1, Christopher Heaney, Tamara James, Chris Conover, Robert Cook-Deegan.   

Abstract

Cystic fibrosis is one of the most commonly tested autosomal recessive disorders in the United States. Clinical cystic fibrosis is associated with mutations in the CFTR gene, of which the most common mutation among Caucasians, DeltaF508, was identified in 1989. The University of Michigan, Johns Hopkins University, and the Hospital for Sick Children, where much of the initial research occurred, hold key patents on cystic fibrosis genetic sequences, mutations, and methods for detecting them. Several patents, including the one that covers detection of the DeltaF508 mutation, are jointly held by the University of Michigan and the Hospital for Sick Children in Toronto, with Michigan administering patent licensing in the United States. The University of Michigan broadly licenses the DeltaF508 patent for genetic testing with >60 providers of genetic testing to date. Genetic testing is now used in newborn screening, diagnosis, and for carrier screening. Interviews with key researchers and intellectual property managers, a survey of laboratories' prices for cystic fibrosis genetic testing, a review of literature on cystic fibrosis tests' cost-effectiveness, and a review of the developing market for cystic fibrosis testing provide no evidence that patents have significantly hindered access to genetic tests for cystic fibrosis or prevented financially cost-effective screening. Current licensing practices for cystic fibrosis genetic testing seem to facilitate both academic research and commercial testing. More than 1000 different CFTR mutations have been identified, and research continues to determine their clinical significance. Patents have been nonexclusively licensed for diagnostic use and have been variably licensed for gene transfer and other therapeutic applications. The Cystic Fibrosis Foundation has been engaged in licensing decisions, making cystic fibrosis a model of collaborative and cooperative patenting and licensing practice.

Entities:  

Mesh:

Year:  2010        PMID: 20393308      PMCID: PMC2914455          DOI: 10.1097/GIM.0b013e3181d7cf7d

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  36 in total

1.  Linkage studies with cystic fibrosis of the pancreas.

Authors:  F H ALLEN; R R DOOLEY; H SHWACHMAN; A G STEINBERG
Journal:  Am J Hum Genet       Date:  1956-09       Impact factor: 11.025

2.  Sequential test for linkage between cystic fibrosis of the pancreas and the MNS locus.

Authors:  N E MORTON; A G STEINBERG
Journal:  Am J Hum Genet       Date:  1956-09       Impact factor: 11.025

3.  Improved results with lung transplantation for cystic fibrosis: a 6-year experience.

Authors:  Federico Venuta; Serena Quattrucci; Erino A Rendina; Tiziano De Giacomo; Edoardo Mercadante; Marco Moretti; Giuseppe Cimino; Giorgio F Coloni
Journal:  Interact Cardiovasc Thorac Surg       Date:  2004-03

4.  The Cystic Fibrosis mutation "arms race": when less is more.

Authors:  Wayne W Grody; Garry R Cutting; Michael S Watson
Journal:  Genet Med       Date:  2007-11       Impact factor: 8.822

Review 5.  The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel.

Authors:  B J Rosenstein; G R Cutting
Journal:  J Pediatr       Date:  1998-04       Impact factor: 4.406

6.  A candidate for the cystic fibrosis locus isolated by selection for methylation-free islands.

Authors:  X Estivill; M Farrall; P J Scambler; G M Bell; K M Hawley; N J Lench; G P Bates; H C Kruyer; P A Frederick; P Stanier
Journal:  Nature       Date:  1987 Apr 30-May 6       Impact factor: 49.962

7.  Severity of cystic fibrosis in patients homozygous and heterozygous for delta F508 mutation.

Authors:  H K Johansen; M Nir; N Høiby; C Koch; M Schwartz
Journal:  Lancet       Date:  1991-03-16       Impact factor: 79.321

8.  Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group.

Authors:  P M Farrell; M R Kosorok; M J Rock; A Laxova; L Zeng; H C Lai; G Hoffman; R H Laessig; M L Splaingard
Journal:  Pediatrics       Date:  2001-01       Impact factor: 7.124

9.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

10.  Mapping of DNA markers linked to the cystic fibrosis locus on the long arm of chromosome 7.

Authors:  S Zengerling; L C Tsui; K H Grzeschik; K Olek; J R Riordan; M Buchwald
Journal:  Am J Hum Genet       Date:  1987-03       Impact factor: 11.025

View more
  7 in total

Review 1.  Do recent US Supreme Court rulings on patenting of genes and genetic diagnostics affect the practice of genetic screening and diagnosis in prenatal and reproductive care?

Authors:  Subhashini Chandrasekharan; Amy L McGuire; Ignatia B Van den Veyver
Journal:  Prenat Diagn       Date:  2014-07-31       Impact factor: 3.050

Review 2.  Patents in genomics and human genetics.

Authors:  Robert Cook-Deegan; Christopher Heaney
Journal:  Annu Rev Genomics Hum Genet       Date:  2010       Impact factor: 8.929

3.  Patently unpatentable: implications of the Myriad court decision on genetic diagnostics.

Authors:  Mildred Cho
Journal:  Trends Biotechnol       Date:  2010-11       Impact factor: 19.536

4.  Cystic Fibrosis Patents: A Case Study of Successful Licensing.

Authors:  Mollie A Minear; Cristina Kapustij; Kaeleen Boden; Subhashini Chandrasekharan; Robert Cook-Deegan
Journal:  LES Nouv       Date:  2013-03-01

Review 5.  Gene patents: a broken incentives system.

Authors:  Yun-Han Huang
Journal:  J Relig Health       Date:  2013-12

6.  Translating personalized medicine using new genetic technologies in clinical practice: the ethical issues.

Authors:  Kelly E Ormond; Mildred K Cho
Journal:  Per Med       Date:  2014       Impact factor: 2.512

7.  DNA patents and diagnostics: not a pretty picture.

Authors:  Julia Carbone; E Richard Gold; Bhaven Sampat; Subhashini Chandrasekharan; Lori Knowles; Misha Angrist; Robert Cook-Deegan
Journal:  Nat Biotechnol       Date:  2010-08       Impact factor: 54.908

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.